Key result
Heart transplantation remains the optimal treatment for end-stage heart failure, with recent expansions of the donor pool through hepatitis C-positive and circulatory death donors showing comparable survival outcomes.
Why the study?
Despite survival benefits, heart transplantation remains limited by graft availability, graft dysfunction, rejection, and long-term non-cardiac complications.
This narrative review highlights that heart transplantation provides a median survival of over 12 years for end-stage heart failure, while outlining ongoing challenges such as graft availability, rejection, and long-term complications.
No takes yet. Share an insight, caveat, or question.
Supports heart transplantation as preferred end-stage HF therapy; leaves open optimization of long-term care amid persistent limitations.
Awad et al. (2022) conducted a review in End-stage heart failure. Heart transplantation was evaluated. Heart transplantation remains the optimal treatment for end-stage heart failure, with recent expansions of the donor pool through hepatitis C-positive and circulatory death donors showing comparable survival outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: